News for ATXI Stock

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit Avenue Therapeutics to Participate in Upcoming Investor Conferences Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds Avenue Therapeutics Announces Reverse Stock Split Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights Avenue Therapeutics Receives Positive Listing Determination from Nasdaq Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Avenue Therapeutics Announces Closing of $5.0 Million Public Offering Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Avenue Therapeutics to Present at Aegis Capital Virtual Conference Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI) Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI) Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol Avenue Therapeutics Stock Trading Halted Today Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) Avenue Therapeutics Announces Closing of Public Offering of Common Stock Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022 Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) Avenue Therapeutics Announces Closing of Public Offering of Common Stock Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis Avenue Therapeutics Provides Regulatory Update for IV Tramadol Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol Avenue Therapeutics Announces Publication of a Review of IV Tramadol Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Avenue Therapeutics Announces Publications in Peer-Reviewed Journals Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders